Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of TDI01 suspension in idiopathic pulmonary fibrosis
CTR20232403Phase 2Active
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd.
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing TDI01 suspension with Placebo (2 arms). Primary endpoint: Change from baseline in forced vital capacity. Started Jan 2024; status: active.
02
Drugs
TDI01
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20232403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232403.